Navigation Links
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference
Date:8/3/2009

FREMONT, Calif., Aug. 3 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC's Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in Boston, MA as part of IBC's Drug Discovery Week. Dr. Thompson has been appointed a member of the conference's scientific advisory board and will deliver the Conference Chair Opening Remarks. In addition, he will give a presentation and participate as a panel moderator.

Dr. Thompson's presentation, titled, "Design and Development of Synthetic siRNAs for Clinical Applications," will describe Quark's pipeline, which includes PF-04523655, a synthetic siRNA in Phase II clinical studies licensed by Pfizer in multiple ophthalmology indications, and QPI-1002, a synthetic siRNA in Phase I/II studies for two renal indications. The presentation will incorporate an update on Quark's clinical studies; a case study on the first siRNA administered systemically to man; and an overview of Quark's strategies to optimize synthetic siRNAs for clinical applications while avoiding off-target effects.

The Industry Leadership Forum panel Dr. Thompson will moderate is titled, "RNA Therapeutics - Are We Leveraging on the Promise?" It will cover the current state of development of siRNA, miRNA, antisense and aptamar therapeutics and examine how companies are capitalizing on the promise of the field. Panelists will include Paul Burke, Ph.D., Executive Director, RNA Therapeutics, Merck & Co., Inc.; Klaus Giese, Ph.D., Chief Scientific Officer, Vice President, Research, Silence Therapeutics AG; and Tod Woolf, Ph.D., President and CEO, RXi Pharmaceuticals Corporation.

<
'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
2. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
5. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
6. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
7. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
8. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
9. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
10. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
11. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...rd Hughes Medical Institute (HHMI) researchers hav...e development of many forms of medulloblastoma, th...ncer., HHMI investigator Huda Y. Zoghbi and coll...ulloblastoma from developing in mice by shutting d... brain cells. The team,s findings, reported in the...
(Date:12/3/2009)... , Massachusetts Does Little to Make Lung...HINGTON, Dec. 3 Today...ed its 3rd Annual Report Card on Lung Cancer . T...eing made against this lethal disease in the state...ncer Alliance (LCA), the only national organizatio...
(Date:12/3/2009)... , More than 1,500 Jobs Listed through A...N, Dec. 3 Today,s White... employment across many professions, including pub...eet the need and connect job seekers to more than ...h CareerMart at http://www.apha.org/about/careers...
(Date:12/3/2009)...YORK (December 3, 2009) -- When the heart is stopp...but their brain is often permanently damaged. Ther...ent,s body temperature is lowered and maintained s...has been shown to mitigate these harmful effects a...st large-scale multicenter study of its kind, phys...
(Date:12/3/2009)...finds higher chemical residue in those who rise an...y News) -- Do you like a cigarette first thing in ...s that those who rise and smoke inhale more nicoti...s might be so, but one of the researchers said he ...more frequent and deeper drags on their cigarettes...
Breaking Medicine News(10 mins):Health News:Researchers identify gene that spurs deadly brain cancer 2Health News:Researchers identify gene that spurs deadly brain cancer 3Health News:Lung Cancer Alliance-Massachusetts Releases 3rd Annual State-Specific Report Card on Lung Cancer 2Health News:Public Health Jobs Site Available to Help Meet Growing Demand 2Health News:Cooling may benefit children after cardiac arrest 2Health News:Early Morning Smokers May Be More Dependent on Nicotine 2
...been in the forefront, monitoring the Herculean ta...ated checks on the documentation of the dealers. /...ught from Navpur in Maharashtra is still in safe c... will be checking the invoices and octroi bills o...
...ya has pledged to donate his body for the "advance...etary of Ganadarpan, Brojo Roy said that, "The chi...cause." Ganadarpan is an NGO with which Bhattachar...ose who have also pledged their bodies for medical...
... Glasgow and discussing on the issue of how to tac...ewed methadone programmes and rehabilitation// ser...atment Conference. Drug abuse is increasing day by...ip, said that there was no overnight solution. Thi...
...rain products. The movement has burst out of the n.../ are available that would have been unthinkable a...the image of whole-grain muesli, rubbery tofu and ...ee-range hot dog vendors. Almost every food p...
...linic. It’s got its branch across the globe. Ameri...senius// Medical Care climbed 46.9% $25.85. It fol...ucrative business. Kidney failure affects the ...d in recent years. As the world's largest dialysis...
...olyphenols. This is essential in preventing period...// Molecules that were found to affect the gums an...attacked and polyphenols is a vital factor in prev...r from periodontitis. This increases when one grow...
Other Medicine News:Health News:Organic food loses its whole-grain image 2Health News:Dialysis Clinics Owned By Fresenius Flourishes Due To Its Customers 2
(Date:12/3/2009)..., Dec. 3 VirtualScopics,...ntitative imaging for clinical trials, announced t... 4D Reconstruction and Visualization" recently rec...e President of Technology and Product Development,...apan has recognized the uniqueness of VirtualScopi...
(Date:12/3/2009)... and NEEDHAM, Massachusetts, December 3 /PRNewswir...change: ORIDN) today announced that the Bavarian R...hs for its RTW (Rettungswagen) medical vehicles. T...assess the ventilation status of a patient as well...tatus such as displaced endotracheal tubes, episod...
(Date:12/2/2009)..., Dec. 2 Reportlinker.com announc...in its catalogue: ,, Hospital Information Syst...tunities ,, http://www.reportlinker.com/p0164...-of-Market-Trends--Opportunities.html ,, Incre...he benefits of using Information Technology in the...
Breaking Medicine Technology:VirtualScopics Receives Issuance in Japan of Prominent Patent 2VirtualScopics Receives Issuance in Japan of Prominent Patent 3Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety 2Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety 3Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety 4Reportlinker Adds Hospital Information Systems - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Hospital Information Systems - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Hospital Information Systems - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Hospital Information Systems - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Hospital Information Systems - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Hospital Information Systems - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Hospital Information Systems - A Global Update of Market Trends & Opportunities 8Vaporized Propylene Glycol a Key Ingredient in Electronic Cigarettes May Prevent Pneumonia Influenza and Other Respiratory Diseases 60489 1Vaporized Propylene Glycol a Key Ingredient in Electronic Cigarettes May Prevent Pneumonia Influenza and Other Respiratory Diseases 60489 21 9 Million Drivers Have Fatigue Related Car Crashes or Near Misses Each Year 60486 11 9 Million Drivers Have Fatigue Related Car Crashes or Near Misses Each Year 60486 21 9 Million Drivers Have Fatigue Related Car Crashes or Near Misses Each Year 60486 31 9 Million Drivers Have Fatigue Related Car Crashes or Near Misses Each Year 60486 4Cell Therapeutics Inc 28CTI 29 to Report Third Quarter Financial Results on November 5 60483 1
...rthwest,Biotherapeutics, Inc. (OTC Bulletin Board:...") today announced the most recent long-term,follo...hase I and Phase,I/II clinical trials with DCVax(R...s with Glioblastoma multiforme, the most lethal ty... 84% of patients who received,DCVax(R)-Brain in th...
...ing acquisition of Organon BioSciences, KENILWORT...SE: SGP ) today announced that the European launc...ith its introduction this week,in Sweden, and that...he,United Kingdom and Germany, with several other ...and in early 2009., "The introduction of BRIDION ...
Other Medicine Technology:Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain 2Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain 3Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain 4Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain 5Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain 6Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex) 2Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex) 3
...immobilization and cervical spine care, one piece ...ost important function of a cervical collar is imm...now is that independent studies prove that Jerome ...ation over the leading one-piece rigid collar, and...
...m support and stabilization for non-operable hip d...otal hip arthroplasty. Neoprene padding is secured...s brace may be ordered with either of our patented... The pelvic posterior panel design allows the prac...
Bledsoe Simple Pelvic Brace
...pe harness with greatly improved wearability and u...asia. Color-coded straps, Velcro fasteners, soft, ...or-coded anterior straps help avoid misapplication...ld lies supine. This patented feature is not found...
Medicine Products: